☰

NordicBioscience

Updating the operating model

Industry
Biotechnology
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of NordicBioscience's published strategy and is not endorsed by, or produced in cooperation with, NordicBioscience. Company website

Strategic priorities

NordicBioscience operates across 4 stated priorities, with the most concrete near-term plan anchored on biomarker commercialization.

Accelerating the transition of 125+ biomarkers from research tools to FDA-supported diagnostic products, exemplified by the PRO-C3 tumor fibrosis Letter of Support and Roche COBAS platform launch.

Maintaining position as Scandinavia's only CAP/CLIA-certified laboratory while scaling capacity to meet pharmaceutical partner demands with 3-day safety parameter turnaround.

Advancing high-stakes collaborations including the Eli Lilly DACRA molecule program targeting obesity and metabolic conditions through therapeutic pipeline expansion.

Challenges we see

  • Operations Manufacturing

    Manual ELISA Dependency

    While Nordic Bioscience operates well-regarded automated analyzers from Roche and Siemens for safety parameters, proprietary ProteinFingerPrint specialty assays require manual ELISA steps that create throughput bottlenecks.

    Tech-to-tech variation impacts reproducibility of clinical trial results, and high-volume pipetting causes repetitive strain incidenties among laboratory technicians.

  • Digital Integration

    Data Fragmentation and Excel Islands

    Scientists perform complex calculations for cell density and growth rate analytics in localized spreadsheets that are not integrated with the Central Laboratory Information Management System.

    Scientists spend 30-40% of their time manually extracting, cleaning, and formatting data, creating significant productivity loss and risks of transcription errors.

  • Digital Operations

    Post-Demerger IT Infrastructure

    The carve-out from Sanos/NBCD required complex IT separation, necessitating dedicated oversight for infrastructure transition and cybersecurity program migration.

    Maintaining separate cybersecurity protocols while enabling data sharing for collaborative clinical trials increases compliance risk and requires costly manual oversight.

  • Compliance Regulatory

    ALCOA++ Audit Trail Compliance

    The FDA Letter of Support for PRO-C3 elevates regulatory expectations for every data point generated, requiring adherence to Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available principles.

    In a hybrid manual step/automated environment, maintaining complete and tamper-proof audit trails requires labor-intensive continuous manual step reviews across paper and electronic records.

  • Operations Manufacturing

    Specialty Report Lead Time

    While safety parameters achieve 3-day turnaround, specialty assay reports require 21-day lead time due to manual processing layers and non-automated workflows.

    Prolonged lead times risk losing market share to faster, more digitized competitors and may delay pharmaceutical contract deliverables.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Manual Data Handling Productivity Loss

    Scientists spend 30-40% of their time on manual data extraction, cleaning, and formatting rather than scientific analysis, with critical biological KPIs tracked in Excel separately from live process trends.

    Implement automated data pipelines using OPC UA and MQTT protocols to bridge manual ELISA assays with central LIMS, creating a Single Source of Truth and eliminating Excel Islands.

  2. Tech-to-Tech Variation in Specialty Assays

    Manual pipetting in specialty ELISA workflows introduces reproducibility variance between technicians, impacting the reliability of clinical trial support and creating RSI risk among laboratory staff.

    Deploy collaborative robotics beyond flowbot ONE capabilities, integrating computer vision for automated quality control to standardize specialty assay execution and reduce occupational incidenties.

  3. Digital Hesitancy and Trust Deficit

    Laboratory staff transitioning from manual to automated workflows experience digital hesitancy and Black Box Anxiety regarding automation algorithms, preferring familiar manual methods despite available digital tools.

    Implement a Culture over Code change management program including UX-First dashboard redesigns and Sandbox testing environments to transform technicians from manual operators to Digital Operators.

  4. Fragmented Post-Demerger Infrastructure

    IT infrastructure segregation following the Sanos/NBCD demerger created a complex Digital Nervous System requiring constant monitoring for cybersecurity and GxP compliance across now-separate entities.

    Build a unified, ontology-based data platform on Industry 4.0 principles from the ground up, establishing secure communication protocols and streamlined data handshake with clinical partners.

  5. High Cost and Duration of Wet Lab Trials

    Drug development efforts with partners like Eli Lilly require extensive physical trials to validate DACRA molecules and other therapeutic candidates, consuming significant time and resources before confirming efficacy.

    Utilize Digital Twin technology to build simulations of the ECM microenvironment, enabling prediction of drug-molecule interactions before expensive physical trials commence, accelerating time-to-market.

What we'd propose

  • Digital Lab

    Laboratory Data Integration Platform

    A comprehensive digital backbone that unifies heterogeneous laboratory equipment data streams, eliminating manual data handling and creating real-time visibility into specialty assay workflows.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Digital CDMO

    Automated Specialty Assay Robotics

    Next-generation collaborative robotics and computer vision system designed to automate manual ELISA workflows, reduce tech-to-tech variation, and eliminate repetitive strain incident risk.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO
  • Digital Lab

    Digital Operator Transformation Program

    A comprehensive change management initiative that transforms laboratory staff from manual technicians to confident Digital Operators through structured onboarding, UX optimization, and trust-building exercises.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    Post-Demerger IT/OT Architecture Consolidation

    A strategic IT infrastructure modernization initiative that establishes secure, GxP-compliant data exchange protocols and unified system architecture following the Sanos/NBCD carve-out.

    • Ontology layer

      A shared semantic model so lab, process, and quality data describe the same things the same way.

      DETAIL

    • Predictive models

      Models trained on the historical data plane that flag deviations before they become scrap.

      DETAIL

    • Decision surfaces

      Single pane of glass that surfaces model output to the right role at the right moment.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    ECM Digital Twin for Drug Development

    An advanced simulation platform that models extracellular matrix dynamics and tissue remodeling processes, enabling in-silico prediction of drug-molecule interactions before physical trials.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what NordicBioscience's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data Integration 45 → 90
Heterogeneous equipment generating data silos; 30-40% scientist time on manual data handling; Excel Islands persist despite LIMS investment
Lab Automation 55 → 85
High-throughput safety automation achieved via Roche/Siemens; specialty ELISA remains manual with RSI risk; flowbot ONE adoption limited
Process Standardization 60 → 90
CAP/CLIA certification achieved; tech-to-tech variation persists in specialty assays; 21-day specialty lead time vs 3-day safety turnaround
Regulatory Compliance 70 → 95
ALCOA++ principles adopted; FDA Letter of Support achieved; IFRS 2024 adoption complete; hybrid manual/digital audit trails require improvement
Digital Culture 40 → 80
Digital hesitancy identified among lab staff; Black Box Anxiety toward automation; change management needed to transform manual mindset
IT/OT Security 50 → 90
Post-demerger infrastructure in flux; cybersecurity protocols require stabilization; GxP compliance maintained but manual oversight intensive

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with NordicBioscience, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].